The value of PET/CT in determining lymph node metastasis of endometrial cancer
Abstract
Objectives: In our study, the role of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (F-18 FDG PET/CT) in determining lymph node metastasis of endometrial cancer was evaluated.
Material and methods: The present retrospectively registered study included 80 patients with endometrial cancer who underwent PET/CT in preoperative period. The patients underwent total hysterectomy with bilateral salpingo-oophorectomy and lymph node dissection. Lymph node status was evaluated in histopathologic examination and PET/CT imaging and, the results were compared.
Results: There were 80 patients (mean age 62 years) in the present study. Lymph node metastasis was detected in five patients, whereas 75 patients had no lymph node metastasis. A total of 1,471 lymph nodes were examined histopathologically, revealing benign findings in 1,433 (pelvic = 1018, paraaortic = 415) and malignant findings in 38 (pelvic = 28, paraaortic = 10) lymph nodes. The accuracy, sensitivity and specificity of PET/CT in determining lymph node metastasis was 95%, 80% and 96% in patient-based evaluation, and 97.4%, 78.9% and 98.6% in lymph node-based evaluation, respectively. The detection sensitivity of PET/CT was 0%, 81.4% and 100% in metastatic lymph nodes with a short diameter of ≤ 4 mm, 5–9 mm and ≥ 10 mm, respectively. PET/CT could detect 73.3% of metastatic lymph nodes that had < 10 mm short diameter.
Conclusions: PET/CT is useful method in detecting lymph node metastasis especially that are disregarded by CT or MR in endometrial cancer. Although PET/CT doesn’t fully replace the surgical staging, its utilization in preoperative period may guide surgical procedure.
Keywords: FDG PET/CTendometrial cancerlymph node metastasis
References
- Signorelli M, Guerra L, Buda A, et al. Role of the integrated FDG PET/CT in the surgical management of patients with high risk clinical early stage endometrial cancer: detection of pelvic nodal metastases. Gynecol Oncol. 2009; 115(2): 231–235.
- Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009; 105(2): 103–104.
- Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet. 2009; 105(2): 109.
- Uharcek P, Mlyncek M, Lajtman E, et al. Prognostic factors in endometrial carcinoma. J Obstet Gynaecol Res. 2008; 34(5): 776–783.
- Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016; 27(1): 16–41.
- Manetta A, Delgado G, Petrilli E, et al. The significance of paraaortic node status in carcinoma of the cervix and endometrium. Gynecol Oncol. 1986; 23(3): 284–290.
- Gal D, Recio FO, Zamurovic D, et al. Lymphvascular space involvement--a prognostic indicator in endometrial adenocarcinoma. Gynecol Oncol. 1991; 42(2): 142–145.
- Kitchener H, Swart AMC, Qian Q, et al. ASTEC study group. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009; 373(9658): 125–136.
- Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008; 100(23): 1707–1716.
- May K, Bryant A, Dickinson HO, et al. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev. 2010(1): CD007585.
- Park JY, Lee JJ, Choi HJ, et al. The Value of Preoperative Positron Emission Tomography/Computed Tomography in Node-Negative Endometrial Cancer on Magnetic Resonance Imaging. Ann Surg Oncol. 2017; 24(8): 2303–2310.
- Connor JP, Andrews JI, Anderson B, et al. Computed tomography in endometrial carcinoma. Obstet Gynecol. 2000; 95(5): 692–696.
- Ryoo UiN, Choi CH, Yoon JiY, et al. MR imaging in endometrial carcinoma as a diagnostic tool for the prediction of myometrial invasion and lymph node metastasis. Cancer Res Treat. 2007; 39(4): 165–170.
- Bollineni VR, Ytre-Hauge S, Bollineni-Balabay O, et al. High Diagnostic Value of 18F-FDG PET/CT in Endometrial Cancer: Systematic Review and Meta-Analysis of the Literature. J Nucl Med. 2016; 57(6): 879–885.
- Crivellaro C, Signorelli M, Guerra L, et al. Tailoring systematic lymphadenectomy in high-risk clinical early stage endometrial cancer: the role of 18F-FDG PET/CT. Gynecol Oncol. 2013; 130(2): 306–311.
- Rockall AG, Sohaib SA, Harisinghani MG, et al. Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J Clin Oncol. 2005; 23(12): 2813–2821.
- Rockall AG, Meroni R, Sohaib SA, et al. Evaluation of endometrial carcinoma on magnetic resonance imaging. Int J Gynecol Cancer. 2007; 17(1): 188–196.
- Kim HJ, Cho A, Yun M, et al. Comparison of FDG PET/CT and MRI in lymph node staging of endometrial cancer. Ann Nucl Med. 2016; 30(2): 104–113.
- Chang MC, Chen JH, Liang JA, et al. 18F-FDG PET or PET/CT for detection of metastatic lymph nodes in patients with endometrial cancer: A systematic review and meta-analysis. Eur J Radiol. 2012; 81(11): 3511–3517.
- Kitajima K, Murakami K, Yamasaki E, et al. Accuracy of 18F-FDG PET/CT in detecting pelvic and paraaortic lymph node metastasis in patients with endometrial cancer. AJR Am J Roentgenol. 2008; 190(6): 1652–1658.
- Kitajima K, Murakami K, Yamasaki E, et al. Accuracy of integrated FDG-PET/contrast-enhanced CT in detecting pelvic and paraaortic lymph node metastasis in patients with uterine cancer. Eur Radiol. 2009; 19(6): 1529–1536.
- Suzuki R, Miyagi E, Takahashi N, et al. Validity of positron emission tomography using fluoro-2-deoxyglucose for the preoperative evaluation of endometrial cancer. Int J Gynecol Cancer. 2007; 17(4): 890–896.
